Key genetic differences between pediatric and adult forms of immune-mediated inflammatory diseases identified

Researchers from the Children's Hospital of Philadelphia (CHOP) have discovered distinct genetic architectures between pediatric and adult forms of immune-mediated inflammatory diseases (IMIDs). Published in the Annals of the Rheumatic Diseases, these findings could lead to advancements in disease classification and precision therapies for adult patients with similar conditions.

IMIDs, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are driven by overactive and dysregulated immune responses that cause increased inflammation. While genome-wide association studies (GWAS) in adults have identified numerous genetic variants for IMIDs, the genetic basis of pediatric-onset IMIDs remains poorly understood.

The CHOP study, which analyzed 18,086 cases and 131,019 controls, revealed that genetic variability contributes to disease risk, with heritability ranging from 28.9% for allergic IMIDs to 61.9% for autoimmune IMIDs. The research identified 39 genome-wide significant variants associated with immune responses, 15 of which were previously unreported.

These variants were shared across different IMID categories, indicating common genetic pathways in pediatric and adult diseases. However, pediatric-onset IMIDs exhibit a distinct genetic architecture shaped by age-specific immune and neurodevelopmental biology. The study's findings highlight the importance of developmental and growth-phase programs in pediatric IMID risk and suggest that these processes could be leveraged for early risk stratification, mechanistic disease subclassification, and prioritization of therapeutic targets in pediatric rheumatology.